Regarding the Wilderness Medical Society Practice Guidelines for Heat-Related Illness

M. Hoffman,T. Hew-Butler,M. Schwellnus

DOI: https://doi.org/10.1016/j.wem.2014.02.003

2014-06-01

Abstract:

What problem does this paper attempt to address?

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Wenjing Ruan,Kejing Ying

DOI: https://doi.org/10.1016/j.prp.2010.03.010

IF: 3.309

2010-01-01

Pathology - Research and Practice

Abstract:For significant improvements to occur in the survival of patients with idiopathic pulmonary fibrosis (IPF), it is necessary to develop novel and more precisely targeted therapies. The selection of future appropriate regimens must critically depend on improved characterization of the molecules driving the pathogenesis of IPF. It is well defined that IPF is characterized by the expression of genes indicating an active tissue remodeling program, including extracellular matrix (ECM) and basement membrane components, as well as myofibroblast-associated and epithelial cell-related genes. A few recent advances are worth mentioning. Pulmonary research demonstrates abnormal expression of insulin-like growth factor (IGF) binding proteins (IGFBPs) in IPF, including human IPF bronchoalveolar lavage (BAL) cells and BAL fluids, human IPF fibroblasts, as well as fibrotic lung tissues of bleomycin-induced mice and IPF patients, analyzed by microarray, reverse transcription-polymerase chain reaction (RT-PCR), ribonuclease protection assay (RPA), Western blot, immunohistochemistry, or enzyme-linked immunosorbent assay (ELISA). Simultaneously, in vitro and in vivo studies indicate the involvement of IGFBPs in the initiation and development of the fibrosis process, including fibroblast activation and transdifferentiation to a myofibroblast phenotype, epithelial–mesenchymal transition (EMT), increased ECM production, and decreased ECM degradation, possibly contributing to the final lung fibrosis. These observations suggest that dysregulation of IGFBPs may be a key factor responsible for the initiation and perpetuation of IPF. Such efforts could lead to potential candidate molecules being exploited for therapeutic manipulation.
Active substances and molecular mechanisms of Astragali Radix and Angelicae Sinensis Radix against idiopathic pulmonary fibrosis effects by network pharmacology and in vitro experiments

Haolin Chu,Shanshan Liu,Shujing Zhang,Shuyan Wang,Hongsheng Chang,Lina Li

DOI: https://doi.org/10.1016/j.cjac.2024.100397

IF: 1.193

2024-05-13

Chinese Journal of Analytical Chemistry

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic disease with an unclear etiology and no effective treatment. This study aims to elucidate the pathogenic mechanism networks involving multiple targets and pathways in IPF. Extracts and metabolites of Astragali Radix (AR) and Angelicae Sinensis Radix (ASR), two well-known traditional Chinese medicines, have demonstrated therapeutic effects on IPF. However, the underlying mechanisms of AR and ASR remain unclear. Utilizing network pharmacology analysis, the disease targets associated with IPF were obtained from the GeneCards database and Online Mendelian Inheritance in Man (OMIM) database. Targets of AR and ASR were identified using the TCM Systems Pharmacology Database and Analysis Platform and Swiss Target Prediction. A proteinprotein interaction (PPI) network was subsequently constructed and analyzed using the STRING database and Cytoscape software. Gene ontology enrichment (GO) analysis and kyoto encyclopedia of genes and genomes (KEGG) analysis were conducted using DAVID. Additionally, a component-target-pathway network were employed to identify the main active components, and molecular docking was performed between these components and proteins encoded by key targets. Finally, in vitro studies were conducted based on network pharmacology. A total of 260 common targets between IPF and drug targets were identified and included in the PPI network, in which TNF, IL-6, STAT3, AKT1, VEGFA, SRC, EGFR, INS, JUN, and IL1B were predicted as key targets. These 260 targets were enriched in the PI3K-AKT signaling pathway, HIF-1 signaling pathway, TNF signaling pathway, MAPK signaling pathway, FOXO signaling pathway, and Pathways in cancer. Docking scores ranged from – 4.1 to – 9.5 kcal/mol, indicating a strong binding affinity between the main active compounds and key targets. In vitro studies have indeed shown that Quercetin and Magnolol can alleviate the expression of epithelial-mesenchymal transition in the A549 cells caused by IL-6. The treatment with AR and ASR resulted in a reduction of mRNA levels for key targets HIF-1α and α-SAM. Additionally, the protein expression levels of P-JAK2/ JAK2, P-STAT3/ STAT3, and α-SMA/ β-Actin were also reduced. These results support the therapeutic potential of AR and ASR in ameliorating pulmonary fibrosis and provide insight into the molecular mechanisms involved in their therapeutic effects.

chemistry, analytical
Systems Bioinformatic Approach to Determine the Pharmacological Mechanisms of Radix Astragali and Radix Angelicae Sinensis in Idiopathic Pulmonary Fibrosis

Yufeng Zhang,Lina Gu,Juan PuYang,Mengying Liu,Qingqing Xia,Weilong Jiang,Mengshu Cao

DOI: https://doi.org/10.4103/pm.pm_9_21

2021-01-01

Pharmacognosy Magazine

Abstract:Background: Earlier meta-analysis has publicized that Radix Astragali (RA) and Radix Angelicae sinensis (RAS) are valuable to pulmonary function and exercise capacity in patients with idiopathic pulmonary fibrosis (IPF). Objectives: The objective of the study was to regulate the pharmacological mechanism of RA and RAS in IPF treatment. Materials and Methods: Microarray datasets for IPF were examined in the Gene Expression Omnibus database and differentially expressed genes (DEGs) were recognized. Active compounds and target genes of RA and RAS were recognized using the Traditional Chinese Medicine Systems Pharmacology platform. The DEGs were combined with the active target genes to construct a medicine-compound-gene network and a protein–protein interaction network using Cytoscape software. Gene ontology function enrichment and Kyoto Encyclopedia of Genes and Genomes pathway enrichment were studied using RGUI. A gene-pathway network was established using Cytoscape and molecular docking was done using AutoDock Tool and AutoDock Vina software. Results: We recognized 1566 DEGs and 40 candidate target genes of RA and RAS acting on IPF. The six key active compounds prophesied were quercetin, kaempferol, stigmasterol, 7-O-methylisomucronulatol, formononetin, and beta-sitosterol. Following network construction and enrichment, the two main pathways were acknowledged, namely the tumor necrosis factor signaling pathway and advanced glycation end (AGE) products receptor for AGE signaling pathway. Preliminary molecular docking to confirm interactions between key compounds and their protein targets in the pathways was carried out. Conclusion: The pharmacological mechanisms of RA and RAS in IPF treatment have been further elucidated, which could show valuable in future studies on their mechanisms of action for the treatment of IPF.
Exploring the role and mechanism of Astragalus membranaceus and radix paeoniae rubra in idiopathic pulmonary fibrosis through network pharmacology and experimental validation

Huanyu Jiang,Rui Zhou,Liping An,Junfeng Guo,Xinhui Hou,Jiao Tang,Fei Wang,Quanyu Du

DOI: https://doi.org/10.1038/s41598-023-36944-1

IF: 4.6

2023-09-05

Scientific Reports

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrotic disease with an unclear etiology and no effective treatment. This study aims to elucidate the pathogenic mechanism networks involving multiple targets and pathways in IPF. Extracts and metabolites of Astragalus membranaceus (AM) and Radix paeoniae rubra (RPR), two well-known traditional Chinese medicines, have demonstrated therapeutic effects on IPF. However, the underlying mechanisms of AM and RPR remain unclear. Utilizing network pharmacology analysis, differentially expressed genes (DEGs) associated with IPF were obtained from the GEO database. Targets of AM and RPR were identified using the TCM Systems Pharmacology Database and Analysis Platform and SwissTargetPrediction. A protein–protein interaction (PPI) network was subsequently constructed and analyzed using the STRING database and Cytoscape software. Gene ontology enrichment analysis and kyoto encyclopedia of genes and genomes analysis were conducted using Metascape. Additionally, a component-target-pathway network and a Sankey diagram were employed to identify the main active components, and molecular docking was performed between these components and proteins encoded by key targets. Finally, in vivo studies were conducted based on network pharmacology. A total of 117 common targets between DEGs of IPF and drug targets were identified and included in the PPI network, in which AKT1 , MAPK3 , HSP90AA1 , VEGFA , CASP3 , JUN , HIF1A , CCND1 , PTGS2 , and MDM2 were predicted as key targets. These 117 targets were enriched in the PI3K-AKT pathway, HIF-1 signaling pathway, apoptosis, and microRNAs in cancer. Astragaloside III, (R)-Isomucronulatol, Astragaloside I, Paeoniflorin, and β-sitosterol were selected as the main active components. Docking scores ranged from − 4.7 to − 10.7 kcal/mol, indicating a strong binding affinity between the main active compounds and key targets. In vivo studies have indeed shown that AM and RPR can alleviate the pathological lung fibrotic damage caused by bleomycin treatment. The treatment with AM and RPR resulted in a reduction of mRNA levels for key targets AKT1 , HSP90AA1 , CASP3 , MAPK3 , and VEGFA . Additionally, the protein expression levels of AKT1 , HSP90AA1 , and VEGFA were also reduced. These results support the therapeutic potential of AM and RPR in ameliorating pulmonary fibrosis and provide insight into the molecular mechanisms involved in their therapeutic effects.

multidisciplinary sciences
Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

Xuanyu Wu,Xiang Xiao,Hanyu Fang,Cuifang He,Hanyue Wang,Miao Wang,Peishu Lan,Fei Wang,Quanyu Du,Han Yang

DOI: https://doi.org/10.3389/fphar.2024.1348708

IF: 5.6

2024-02-14

Frontiers in Pharmacology

Abstract:Background: The etiological underpinnings of gastroesophageal reflux disease (GERD) and idiopathic pulmonary fibrosis (IPF) remain elusive, coupled with a scarcity of effective therapeutic interventions for IPF. Angelicae sinensis radix (ASR, also named Danggui) is a Chinese herb with potential anti-fibrotic properties, that holds promise as a therapeutic agent for IPF. Objective: This study seeks to elucidate the causal interplay and potential mechanisms underlying the coexistence of GERD and IPF. Furthermore, it aims to investigate the regulatory effect of ASR on this complex relationship. Methods: A two-sample Mendelian randomization (TSMR) approach was employed to delineate the causal connection between gastroesophageal reflux disease and IPF, with Phennoscanner V2 employed to mitigate confounding factors. Utilizing single nucleotide polymorphism (SNPs) and publicly available microarray data, we analyzed potential targets and mechanisms related to IPF in GERD. Network pharmacology and molecular docking were employed to explore the targets and efficacy of ASR in treating GERD-related IPF. External datasets were subsequently utilized to identify potential diagnostic biomarkers for GERD-related IPF. Results: The IVW analysis demonstrated a positive causal relationship between GERD and IPF (IVW: OR = 1.002, 95%CI: 1.001, 1.003; p < 0.001). Twenty-five shared differentially expressed genes (DEGs) were identified. GO functional analysis revealed enrichment in neural, cellular, and brain development processes, concentrated in chromosomes and plasma membranes, with protein binding and activation involvement. KEGG analysis unveiled enrichment in proteoglycan, ERBB, and neuroactive ligand-receptor interaction pathways in cancer. Protein-protein interaction (PPI) analysis identified seven hub genes. Network pharmacology analysis demonstrated that 104 components of ASR targeted five hub genes (PDE4B, DRD2, ERBB4, ESR1, GRM8), with molecular docking confirming their excellent binding efficiency. GRM8 and ESR1 emerged as potential diagnostic biomarkers for GERD-related IPF (ESR1: AUC GERD = 0.762, AUC IPF = 0.725; GRM8: AUC GERD = 0.717, AUC IPF = 0.908). GRM8 and ESR1 emerged as potential diagnostic biomarkers for GERD-related IPF, validated in external datasets. Conclusion: This study establishes a causal link between GERD and IPF, identifying five key targets and two potential diagnostic biomarkers for GERD-related IPF. ASR exhibits intervention efficacy and favorable binding characteristics, positioning it as a promising candidate for treating GERD-related IPF. The potential regulatory mechanisms may involve cell responses to fibroblast growth factor stimulation and steroidal hormone-mediated signaling pathways.

pharmacology & pharmacy
Unraveling the mechanism of ethyl acetate extract from Prismatomeris connata Y. Z. Ruan root in treating pulmonary fibrosis: insights from bioinformatics, network pharmacology, and experimental validation

Sizheng Li,Guang Hu,Lian Kuang,Tianyu Zhou,Haiyan Jiang,Fei Pang,Jie Li,Xinyi Chen,Jie Bao,Wanfang Li,Chuangjun Li,Menglin Li,Lulu Wang,Dongming Zhang,Jinlan Zhang,Zengyan Yang,Hongtao Jin

DOI: https://doi.org/10.3389/fimmu.2023.1330055

IF: 7.3

2024-01-08

Frontiers in Immunology

Abstract:Introduction Pulmonary fibrosis is a terminal lung disease characterized by fibroblast proliferation, extracellular matrix accumulation, inflammatory damage, and tissue structure destruction. The pathogenesis of this disease, particularly idiopathic pulmonary fibrosis (IPF), remains unknown. Macrophages play major roles in organ fibrosis diseases, including pulmonary fibrosis. The phenotype and polarization of macrophages are closely associated with pulmonary fibrosis. A new direction in research on anti-pulmonary fibrosis is focused on developing drugs that maintain the stability of the pulmonary microenvironment. Methods We obtained gene sequencing data and clinical information for patients with IPF from the GEO datasets GSE110147, GSE15197, GSE24988, GSE31934, GSE32537, GSE35145, GSE53845, GSE49072, GSE70864, and GSE90010. We performed GO, KEGG enrichment analysis and GSEA analysis, and conducted weighted gene co-expression network analysis. In addition, we performed proteomic analysis of mouse lung tissue. To verify the results of bioinformatics analysis and proteomic analysis, mice were induced by intratracheal instillation of bleomycin (BLM), and gavaged for 14 days after modeling. Respiratory function of mice in different groups was measured. Lung tissues were retained for histopathological examination, Western Blot and real-time quantitative PCR, etc. In addition, lipopolysaccharide, interferon-γ and interleukin-4 were used to induce RAW264.7 cells for 12h in vitro to establish macrophage inflammation and polarization model. At the same time, HG2 intervention was given. The phenotype transformation and cytokine secretion of macrophages were investigated by Western Blot, RT-qPCR and flow cytometry, etc. Results Through bioinformatics analysis and experiments involving bleomycin-induced pulmonary fibrosis in mice, we confirmed the importance of macrophage polarization in IPF. The analysis revealed that macrophage polarization in IPF involves a change in the phenotypic spectrum. Furthermore, experiments demonstrated high expression of M2-type macrophage-associated biomarkers and inducible nitric oxide synthase, thus indicating an imbalance in M1/M2 polarization of pulmonary macrophages in mice with pulmonary fibrosis. Discussion Our investigation revealed that the ethyl acetate extract (HG2) obtained from the roots of Prismatomeris connata Y. Z. Ruan exhibits therapeutic efficacy against bleomycin-induced pulmonary fibrosis. HG2 modulates macrophage polarization, alterations in the TGF-β/Smad pathway, and downstream protein expression in the context of pulmonary fibrosis. On the basis of our findings, we believe that HG2 has potential as a novel traditional Chinese medicine component for treating pulmonary fibrosis.

immunology
Author ' s response to reviews Title : Simultaneous copy number gains of NUPR 1 and ERBB 2 predicting poor prognosis in early-stage breast cancer

Seung-Hyun Jung

Abstract:
DNA methylation modification in Idiopathic pulmonary fibrosis

Lu Ren,Yan-Fen Chang,Shi-He Jiang,Xiao-Hong Li,Hai-Peng Cheng

DOI: https://doi.org/10.3389/fcell.2024.1416325

IF: 5.5

2024-06-11

Frontiers in Cell and Developmental Biology

Abstract:Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and irreversible interstitial lung disease with a prognosis worse than lung cancer. It is a fatal lung disease with largely unknown etiology and pathogenesis, and no effective therapeutic drugs render its treatment largely unsuccessful. With continuous in-depth research efforts, the epigenetic mechanisms in IPF pathogenesis have been further discovered and concerned. As a widely studied mechanism of epigenetic modification, DNA methylation is primarily facilitated by DNA methyltransferases (DNMTs), resulting in the addition of a methyl group to the fifth carbon position of the cytosine base, leading to the formation of 5-methylcytosine (5-mC). Dysregulation of DNA methylation is intricately associated with the advancement of respiratory disorders. Recently, the role of DNA methylation in IPF pathogenesis has also received considerable attention. DNA methylation patterns include methylation modification and demethylation modification and regulate a range of essential biological functions through gene expression regulation. The Ten-Eleven-Translocation (TET) family of DNA dioxygenases is crucial in facilitating active DNA demethylation through the enzymatic conversion of the modified genomic base 5-mC to 5-hydroxymethylcytosine (5-hmC). TET2, a member of TET proteins, is involved in lung inflammation, and its protein expression is downregulated in the lungs and alveolar epithelial type II cells of IPF patients. This review summarizes the current knowledge of pathologic features and DNA methylation mechanisms of pulmonary fibrosis, focusing on the critical roles of abnormal DNA methylation patterns, DNMTs, and TET proteins in impacting IPF pathogenesis. Researching DNA methylation will enchance comprehension of the fundamental mechanisms involved in IPF pathology and provide novel diagnostic biomarkers and therapeutic targets for pulmonary fibrosis based on the studies involving epigenetic mechanisms.

cell biology,developmental biology
Complex Involvement of the Extracellular Matrix, Immune Effect, and Lipid Metabolism in the Development of Idiopathic Pulmonary Fibrosis

Weiping Qian,Shu Xia,Xiaoyun Yang,Jiaying Yu,Bingpeng Guo,Zhengfang Lin,Rui Wei,Mengmeng Mao,Ziyi Zhang,Gui Zhao,Junye Bai,Qian Han,Zhongfang Wang,Qun Luo

DOI: https://doi.org/10.3389/fmolb.2021.800747

IF: 6.113

2022-01-31

Frontiers in Molecular Biosciences

Abstract:Background and objective: Idiopathic pulmonary fibrosis (IPF) is an aggressive fibrotic pulmonary disease with spatially and temporally heterogeneous alveolar lesions. There are no early diagnostic biomarkers, limiting our understanding of IPF pathogenesis. Methods: Lung tissue from surgical lung biopsy of patients with early-stage IPF ( n = 7), transplant-stage IPF ( n = 2), and healthy controls ( n = 6) were subjected to mRNA sequencing and verified by real-time quantitative PCR (RT-qPCR), immunohistochemistry, Western blot, and single-cell RNA sequencing (scRNA-Seq). Results: Three hundred eighty differentially expressed transcripts (DETs) were identified in IPF that were principally involved in extracellular matrix (ECM) remodeling, lipid metabolism, and immune effect. Of these DETs, 21 (DMD, MMP7, POSTN, ECM2, MMP13, FASN, FADS1, SDR16C5, ACAT2, ACSL1, CYP1A1, UGT1A6, CXCL13, CXCL5, CXCL14, IL5RA, TNFRSF19, CSF3R, S100A9, S100A8, and S100A12) were selected and verified by RT-qPCR. Differences in DMD, FASN, and MMP7 were also confirmed at a protein level. Analysis of scRNA-Seq was used to trace their cellular origin to determine which lung cells regulated them. The principal cell sources of DMD were ciliated cells, alveolar type I/II epithelial cells (AT cells), club cells, and alveolar macrophages (AMs); MMP7 derives from AT cells, club cells, and AMs, while FASN originates from AT cells, ciliated cells, and AMs. Conclusion: Our data revealed a comprehensive transcriptional mRNA profile of IPF and demonstrated that ECM remodeling, lipid metabolism, and immune effect were collaboratively involved in the early development of IPF.

biochemistry & molecular biology
Mushroom Inonotus sanghuang alleviates experimental pulmonary fibrosis: Implications for therapy of pulmonary fibrosis

Xing Su,Kun Liu,Yu Xie,Mengdi Zhang,Xiao Wu,Yijie Zhang,Junpeng Wang

DOI: https://doi.org/10.1016/j.biopha.2020.110919

2021-01-01

Abstract:Mushroom Inonotus sanghuang has been characterized as a traditional medicine in China and has pharmacological activities to treat inflammation, gastroenteric dysfunction, and cancer. Recently, we reported the impact of Inonotus sanghuang extract (ISE) from ethyl acetate fraction on bleomycin (BLM)-induced acute lung injury in mice. Here, we aimed to investigate ISE's impact on pulmonary fibrosis using in vivo and in vitro models and the underlying mechanisms. To evaluate pulmonary fibrosis, female C57BL/6 mice fed ISE (0% or 0.6% in diet) for 4 weeks were instilled intratracheally with BLM and then continued the same diet before the end of the experiment. A549 cells were used to evaluate the epithelial-mesenchymal transition (EMT). Feeding ISE improved BLM-treated mice's survival via decreasing lung infiltrating cells and fibrosis, followed by reducing hydroxyproline content, collagen deposition, and mesenchymal markers (α-SMA and vimentin) while increasing epithelial marker E-cadherin. ISE also suppressed the TGF-β expression, Smad2/3 phosphorylation, and EMT-related transcription factor Snail upon BLM instillation. Iin vitro study demonstrated that ISE inhibited TGF-β-induced EMT-like phenotype and cell behaviors, the expression of α-SMA and vimentin, and prevented E-cadherin reduction of A549 cells. Consistent with in vivo study, ISE abrogated p-Smad2/3, and Snail expression. Finally, the influence of ISE on EMT was not due to ISE toxicity. Our findings indicated that ISE effectively attenuated BLM-induced lung fibrosis. These ISE properties were thought to be involved in interfering TGF-β, Smad2/3 phosphorylation, and EMT process, suggesting that the material has the potential health benefits to improve lung fibrosis.

pharmacology & pharmacy,medicine, research & experimental
Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis

Peipei Liu,Shengnan Yang,Zai Wang,Huaping Dai,Chen Wang

DOI: https://doi.org/10.3389/fphar.2021.670146

IF: 5.6

2021-07-28

Frontiers in Pharmacology

Abstract:Background: Idiopathic pulmonary fibrosis (IPF) is disease with high mortality, and its effective treatment is limited. Shenfu injection is a traditional Chinese medicine which can improve circulation and protect cells. In this study, we aimed to investigate the feasibility and mechanism of Shenfu injection in the treatment of IPF. Methods: The components and targets of Shenfu injection were mainly retrieved from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) database. The targets of Shenfu injection were standardized by UniProt database. The Genecards and OMIM databases was used to search for IPF-related genes. The Venn diagram of gene intersection was drawn using the OmicStudio tools, and the protein-protein interaction network was visualized using the Cytoscape 3.7.2 software. Moreover, the metascape online software was applied to explore the enriched Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and the Cytoscape 3.7.2 software was used to construct the target-pathway network. Molecular docking was used to visualize the interactions between the main active compounds and targeted proteins. Animal experiments were performed to validate the effects and mechanisms of Shenfu injection. Results: We obtained 46 co-targets of Shenfu injection and IPF. Among the hub target genes, several genes with important functions were enriched, including TNF, IL-6, IL-1B, TP53, JUN, CASP3 and CASP8. The pathway enrichment analysis for the hub target genes identified pathways in infection/inflammation, apoptosis and cancer. Molecular docking results showed that the main active compound Ginsenoside Re had high affinity to the core target proteins. These results suggested that Shenfu injection may have a positive effect in the treatment of IPF. Consistent with this finding, animal experiments showed that Shenfu injection significantly reduced pulmonary fibrosis in a mouse model with inhibition of apoptosis and inflammation by downregulating IL-1β, caspase-3 and phosphorylated NF-κB. Conclusion: Our results demonstrated that Shenfu injection efficiently alleviate bleomycin-induced pulmonary fibrosis through multi-targets in inflammation-, apoptosis- and cancer-related pathways, which provided first evidence and reference to the feasibility of Shenfu injection in the treatment of IPF.

pharmacology & pharmacy
Genes related to N6-methyladenosine in the diagnosis and prognosis of idiopathic pulmonary fibrosis

Jingcheng Zhang,Ying Zhang,Ziyuan Wang,Jiachao Zhao,Zhenyu Li,Keju Wang,Lin Tian,Baojin Yao,Qibiao Wu,Tan Wang,Jing Wang

DOI: https://doi.org/10.3389/fgene.2022.1102422

IF: 3.7

2023-01-04

Frontiers in Genetics

Abstract:Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive pulmonary fibrotic disease with unknown etiology and poor outcomes. It severely affects the quality of life. In this study, we comprehensively analyzed the expression of N6-methyladenosine (m6A) RNA methylation regulators using gene expression data from various tissue sources in IPF patients and healthy volunteers. Methods: The gene expression matrix and clinical characteristics of IPF patients were retrieved from the Gene Expression Omnibus database. A random forest model was used to construct diagnosis signature m6A regulators. Regression analysis and correlation analysis were used to identify prognosis m6A regulators. Consensus cluster analysis was used to construct different m6A prognosis risk groups, then functional enrichment, immune infiltration and drug sensitivity analysis were performed. Result: Five candidate m6A genes from lung tissue were used to predict the incidence, and the incidence was validated using datasets from bronchoalveolar lavage fluid (BALF) and peripheral blood mononuclear cells. Subsequently, the BALF dataset containing outcomes data was used for the prognosis analysis of m6A regulators. METTL14 , G3BP2 , and ZC3H13 were independent protective factors. Using correlation analysis with lung function in the lung tissue-derived dataset, METTL14 was a protective factor in IPF. Based on METTL14 and G3BP2 , a consensus cluster analysis was applied to distinguish the prognostic m6A regulation patterns. The low-risk group’s prognosis was significantly better than the high-risk group. Biological processes regulated by various risk groups included fibrogenesis and cell adhesion. Analysis of immune cell infiltration showed upregulation of neutrophils in the m6A high-risk group. Subsequently, five m6A high-risk group sensitive drugs and one m6A low-risk group sensitive drug were identified. Discussion: These findings suggest that m6A regulators are involved in the diagnosis and prognosis of IPF, and m6A patterns are a method to identify IPF outcomes.

genetics & heredity
Integrative analysis of the efficacy and pharmacological mechanism of Xuefu Zhuyu decoction in idiopathic pulmonary fibrosis via evidence-based medicine, bioinformatics, and experimental verification

Huizhe Zhang,Haibing Hua,Jian Liu,Cong Wang,Chenjing Zhu,Qingqing Xia,Weilong Jiang,Xiangjin Cheng,Xiaodong Hu,Yufeng Zhang

DOI: https://doi.org/10.1016/j.heliyon.2024.e38122

IF: 3.776

2024-09-20

Heliyon

Abstract:Objective: We used evidence-based medicine, bioinformatics and experimental verification to comprehensively analyze the efficacy and pharmacological mechanism of Xuefu Zhuyu decoction (XFZYD) in the treatment of idiopathic pulmonary fibrosis (IPF). Methods: Major databases were retrieved for randomized controlled trials (RCTs) of XFZYD treating IPF to perform meta-analysis. Active ingredients and target genes of XFZYD were identified from the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). IPF-related differentially expressed genes (DEGs) were identified from the Gene Expression Omnibus (GEO) database. The RGUI software was utilized for Gene Ontology (GO) functional enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. The ingredient-target and protein-protein interaction (PPI) networks were achieved through Cytoscape software and the STRING database to identify the key compounds and target proteins. Molecular docking was performed using AutoDockTool and AutoDock Vina software. The effect between key compounds and target proteins was verified in animal experiments. Results: Six RCTs were included for meta-analysis, which uncovered that the total effective rate of clinical efficacy was higher in the experimental group than control group. Then, 156 active ingredients and 254 target genes of XFZYD, and 1,566 IPF-related DEGs were identified. The intersection analysis identified 48 target genes correlating with 130 active ingredients of XFZYD treating IPF. GO functional enrichment, KEGG pathway enrichment, ingredient-target network and PPI network were achieved. Following the identification of key compounds and target proteins, we performed molecular docking. Ultimately, our research focused on the key compound quercetin for experimental validation to assess its interactions with two key target proteins, JUN and PTGS2. Conclusion: The effectiveness of XFZYD on IPF has been substantiated through evidence-based medicine. The pharmacological mechanism of XFZYD for IPF treatment involves a complex interplay of various compounds and targets, with quercetin exerting pronounced impacts on JUN and PTGS2 proteins.
Pharmacological mechanism of Astragalus and Angelica in the treatment of idiopathic pulmonary fibrosis based on network pharmacology

Yufeng Zhang,Weilong Jiang,Qingqing Xia,Jia Qi,Mengshu Cao

DOI: https://doi.org/10.1016/j.eujim.2019.101003

IF: 1.813

2019-01-01

European Journal of Integrative Medicine

Abstract:Introduction: Herbal medicine is varied and complex, and research on multi-component, multi-target and multi-pathways of Astragalus and Angelica is lacking. This study aimed to study the pharmacological mechanism of Astragalus and Angelica in the treatment of idiopathic pulmonary fibrosis (IPF) using on network pharmacology. Methods: The main active components, corresponding targets and target genes of Astragalus and Angelica were searched by TCMSP and UniProt database. The target genes of IPF were obtained by GeneCards database and the target genes of active components were intersected with IPF target genes to obtain predictive targets of Astragalus and Angelica acting on IPF. The medicine-compound-target-disease network was constructed by Cytoscape3.6.0 software. The protein protein interaction network was constructed by STRING database to select the key target genes. The DAVID database and KEGG PATHWAY Database were used to analysis the gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Results: Sixty-nine overlapping genes were obtained by intersecting 100 compound target genes with 2231 IPF target genes, corresponding to 17 effective compounds, including 15 compounds from Astragalus and two compounds from Angelica. GO enrichment showed the main biological functions of potential genes of Astragalus and Angelica in the treatment of IPF. KEGG pathway enrichment showed the main pathways of Astragalus and Angelica in the treatment of IPF. Conclusion: In this study, the target and mechanism of the components of Astragalus and Angelica in the treatment of IPF have been systematically discussed, and have provided ideas for future clinical research.
Integrating network pharmacology, experimental validation and molecular docking to reveal the alleviation of Yinhuang granule on idiopathic pulmonary fibrosis

Zeqi Wu,Ruijia Shi,Shihao Yan,Shaobo Zhang,Bin Lu,Zhenlin Huang,Lili Ji

DOI: https://doi.org/10.1016/j.phymed.2024.155368

IF: 6.656

2024-01-18

Phytomedicine

Abstract:Background Idiopathic pulmonary fibrosis (IPF) is a chronic disease characterized by the abnormal proliferation of fibroblast and excessive deposition of extracellular matrix (ECM), accompanied by inflammation and ultimately respiratory failure. Yinhuang granule (YHG), with clinical properties of clearing heat, detoxifying and anti-inflammation, is commonly used to heal upper respiratory diseases in China for decades. Purpose To explore the improvement of YHG on bleomycin (BLM)-induced IPF in mice and its possible engaged mechanism. Methods The mortality rate was recorded, lung function was determined and hematoxylin-eosin (H&E) staining was carried out to explore the alleviation of YHG on BLM-caused IPF in mice. Hydroxyproline, collagen I and collagen III contents were detected, and Sirius red and Masson staining were conducted to evaluate YHG's alleviation on lung fibrosis. The underlying mechanism was predicted by network pharmacology, and confirmed by Real-time polymerase chain reaction (RT-PCR), Western-blot (WB) and enzyme linked immunosorbent assay (ELISA). The binding affinity between related key proteins and active compounds in YHG was calculated by using molecular docking, and further validated by cellular thermal shift assay (CESTA). Results YHG (400, 800 mg/kg) weakened lung damage and pulmonary fibrosis in mice induced by BLM. Network pharmacology and experimental validation displayed that inflammation and angiogenesis participated in the YHG-provided improvement on IPF, and key involved molecules included tumor necrosis factor- α (TNF α ), vascular endothelial growth factor-A (VEGFA), interleukine-6 (IL-6), etc. The data of molecular docking presented that some main active compounds from YHG had a high binding affinity with TNFR1 or VEGFR2, and some of them were further validated by CESTA. Conclusion YHG effectively improved the BLM-induced IPF in mice via reducing inflammation and angiogenesis.

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
Mechanistic Insights into the Treatment of Pulmonary Fibrosis with Bioactive Components from Traditional Chinese Medicine Via Matrix Stiffness-Mediated EMT

Kangchen Li,Han Liu,Mingyan Li,Meihao Sun,Xiling Peng,Yuanyuan Wu,Yange Tian,Xinguang Liu,Jiansheng Li

DOI: https://doi.org/10.1016/j.phymed.2024.156266

2024-01-01

Abstract:Background Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited therapeutic options. Our previous research has shown that the Jinshui Huanxian formula (JHF) is effective in treating IPF. However, the biomechanical mechanisms of its refined components, known as the effective-component compatibility of JHF II (ECC-JHF II), are not well understood. Purpose This study aims to explore how bioactive components from traditional Chinese medicine (TCM) impact the biomechanical progression of pulmonary fibrosis. Study design and methods A mouse model of pulmonary fibrosis was established by a single intratracheal instillation of bleomycin. Pulmonary function, pathological changes, collagen deposition, lung tissue stiffness, and EMT markers were evaluated at the end of the study. Polyethylene glycol hydrogels with adjustable stiffness were used to mimic both normal and pathological lung conditions. The effects of ECC-JHF II on matrix stiffness-mediated EMT were assessed by quantitative real-time PCR, western blot, and immunofluorescence. The biomechanical mechanisms underlying ECC-JHF II on EMT and pulmonary fibrosis were verified both in vivo and in vitro. Results ECC-JHF II significantly improved bleomycin-induced pulmonary fibrosis in mice, manifested as increased tidal volume and 50% tidal volume expiratory flow, reduced lung tissue stiffness, and decreased EMT markers. Histopathological analysis showed reduced inflammation, alveolar damage, and collagen deposition. In vitro, ECC-JHF II reversed the EMT phenotypic transition induced by substrate stiffness, demonstrated by the upregulation of E-cadherin, occludin, and zonula occluden-1, and the downregulation of N-cadherin, vimentin, caldesmon 1 and tropomyosin 1. Moreover, ECC-JHF II could inhibit integrin/ROCK/MRTF signaling in vitro and in vivo. Silencing integrin β1 or activating it with pyrintegrin further confirmed the role of integrin β1 in the mechanotransduction pathway and the efficacy of ECC-JHF II. Conclusion Taken together, the findings of this study indicate that ECC-JHF II exerts a therapeutic effect on pulmonary fibrosis through the attenuation of lung tissue stiffness and inhibition of EMT, potentially via the integrin/ROCK/MRTF signaling pathway.
Screening study on significant Chinese herb for anti-idiopathic pulmonary fibrosis by combining clinical experience prescriptions and molecular dynamics simulation technologies

Haiting Yan,Beibei He,Li He,Hua Ye

DOI: https://doi.org/10.1080/07391102.2023.2263792

Abstract:Various techniques such as data mining, network pharmacology, molecular docking and molecular dynamics simulation were used in this study to screen and validate effective herbal medicines for the treatment of idiopathic pulmonary fibrosis (IPF) and to reveal their mechanisms of action at the molecular level. The use of this approach will provide new tools and ideas for future drug screening, especially for the application of herbal medicines in the treatment of complex diseases. Among them, the five identified core targets, including IL6, TP53, AKT1, VEGFA, and TNF, as well as a series of major active compounds, will be important references for future anti-IPF drug development. This information will accelerate the discovery and development of relevant drugs. Meanwhile, this study further confirmed the potential value of four Chinese herbal medicines, including Gancao, Danshen, Huangqin, and Sanqi, in the treatment of IPF. This will promote more clinical trials and practices to confirm and optimise the application of these herbs. Finally, this study is an important theoretical guide to enhance the advantages of Chinese herbal medicines in the prevention and treatment of major and difficult diseases, as well as to understand and utilise the potential efficacy of Chinese herbal medicines. This will further promote the scientific research and clinical application of herbal medicines and provide more possibilities for future disease treatmentCommunicated by Ramaswamy H. Sarma.
Development of early-flowering Kabuli chickpea with compound and simple leaves

D. Bonfil,O. Goren,I. Mufradi,J. Lichtenzveig,S. Abbo

DOI: https://doi.org/10.1111/J.1439-0523.2007.01343.X

2007-04-01

Abstract:Terminal drought is a major constraint to chickpea (Cicer arietinum L.) production. Autumn sowing and early flowering have been suggested as ways to benefit from the winter rains in short rainy seasons under dryland cropping. High-yielding, late-flowering, simpleleafed (slv/slv) chickpea cultivars with good field resistance to Ascochyta blight have been bred recently. Changing plant architecture, by altering leaf shape, may affect agronomic performance. As no information is available on the effect of leaf shape on phenology and seed yield, this study was aimed at: (i) introducing the simple leaf trait into an early-flowering chickpea background; (ii) comparing the grain yield of the two leaf types in early vs. late flowering backgrounds and (iii) producing breeding lines combining early flowering, large seeds and Ascochyta tolerance with both leaf types. Hybrid progeny were studied from the cross of Sanford (slv/slv) and ICC7344, (compound, SLV/SLV). Four early-podding, F8 breeding lines were selected with either simple or compound leaves. In three different field experiments under dryland conditions (334–379 mm), they yielded ca. 1.4 t/ha as compared with 1.0 t/ha in the standard Israeli Yarden on one site, but no significant differences in yield were obtained in the other two experiments.
Combined Transcriptomic and Proteomic Analysis Reveals the Mechanism of Xing-Qi-Huo-Xue Granules on BLM-induced Pulmonary Fibrosis in Rats

Xin Gao,Yaling Han,Hai Jiang,Yawei Hao,G. Li,YuWei Zhang,Shanliang Hu,Yangfeng Su,Quanyu Du,Fei Wang

DOI: https://doi.org/10.21203/rs.3.rs-3909911/v1

2024-01-01

Abstract:Background Pulmonary fibrosis is a phenotype of many lung disease pathologies, characterized by alveolar structure destruction, extracellular matrix anomalous accumulation, and abnormal collagen deposition. Traditional Chinese medicine is becoming increasingly important in treating pulmonary fibrosis, and Xing-Qi-Huo-Xue (XQHX) granules have been clinically proven effective, but the underlying mechanism is unclear. Purpose In this experiment, The mechanism of XQHX in treating rats with PF was elucidated by combined transcriptomic and proteomic analyses. Method The main components of XQHX granules was detected by liquid chromatography/mass spectrometry (LC/MS) first. A bleomycin (BLM)-induced rat model was established and lung histology was assessed by hematoxylin eosin and Masson's stain. Rat lung tissues were subjected to transcriptome and proteome sequencing, and bioinformatic analyses of differential genes/proteins were performed. Collagen I/III mRNA expression levels were determined by RT-qPCR, and lung hydroxyproline (HYP) levels were determined by colorimetric assay. Results A total of 16 main compounds including agroastragaloside IV, astragaloside I, astragaloside II, etc. in XQHX were detected by LC/MS. XQHX significantly improved BLM-induced lung tissue structure destruction and HYP content. Furthermore, XQHX inhibited lung tissue mRNA expression of collagens I, and III. Bioinformatics analysis showed that 1657 genes and 590 proteins were differentially expressed in the normal control group (N) compared to the BLM-induced control group (P), and 2.46 g/kg XQHX- treated group (X) had 805 genes and 499 proteins differentially expressed. Then we identified that XQHX exerts an anti-fibrotic effect by regulating arginine (Arg1), which is involved in the arginine biosynthesis pathway and the arginine and proline metabolism pathway. Conclusion Our results suggest that XQHX reduces arginase biosynthesis by down-regulating Arg1 expression as a central mechanism and potential therapeutic approach to prevent BLM-induced pulmonary fibrosis.
Chinese medicine as a therapeutic option for pulmonary fibrosis: Clinical efficacies and underlying mechanisms

Yanwei Hao,Jiaxin Li,Lijuan Dan,Xuanyu Wu,Xiang Xiao,Han Yang,Rui Zhou,Bin Li,Fei Wang,Quanyu Du

DOI: https://doi.org/10.1016/j.jep.2023.116836

IF: 5.195

2023-07-09

Journal of Ethnopharmacology

Abstract:Ethnic pharmacological relevance Pulmonary fibrosis (PF) is a fibrotic interstitial lung disease caused by continuous damage and excessive repair of alveolar epithelial cells, the pathogenesis of which is not fully understood. At present, the incidence of PF has increased significantly around the world. The therapeutic arsenals against PF are relatively limited, with often poor efficacy and many adverse effects. As a conventional and effective therapeutic strategy, traditional Chinese medicine (TCM) has been widely applied in treating lung fibrosis for thousands of years in China. Due to the multi-ingredient, multi-target characteristics, Chinese medicines possess promising clinical benefits for PF treatment. Aim of this review This review aims to systematically analyze the clinical efficacy of Chinese medicine on PF, and further summarize the relevant mechanisms of Chinese medicine treating PF in preclinical studies, in order to provide a comprehensive insight into the beneficial effects of Chinese medicines on PF. Methods Eight major Chinese and English databases were searched from database inception up to October 2022, and all randomized clinical trials (RCTs) investigating the effects of Chinese medicine intervention on effectiveness and safety in the treatment of PF patients were included. Subsequently, preclinical studies related to the treatment of PF in Chinese medicine, including Chinese medicine compounds, Chinese herbal materials and extracts, and Chinese herbal formulas (CHFs) were searched through PubMed and Web of science to summarize the related mechanisms of Chinese medicine against PF. Results A total of 56 studies with 4019 patients were included by searching the relevant databases. Total clinical efficacy, pulmonary function, blood gas analysis, lung high resolution CT (HRCT), 6 min walk test (6-MWT), St George's Respiratory Questionnaire (SGRQ) scores, clinical symptom scores, TCM syndrome scores and other outcome indicators related to PF were analyzed. Besides, numerous preclinical studies have shown that many Chinese medicine compounds, Chinese herbal materials and extracts, and CHFs play a preventive and therapeutic role in PF by reducing oxidative stress, ameliorating inflammation, inhibiting epithelial-mesenchymal transition and myofibroblasts activation, and regulating autophagy and apoptosis. Conclusion Chinese medicines show potential as supplements or substitutes for treating PF. And studies on Chinese medicines will provide a new approach to better management of PF.

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences

Regarding the Wilderness Medical Society Practice Guidelines for Heat-Related Illness

Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis?

Active substances and molecular mechanisms of Astragali Radix and Angelicae Sinensis Radix against idiopathic pulmonary fibrosis effects by network pharmacology and in vitro experiments

Systems Bioinformatic Approach to Determine the Pharmacological Mechanisms of Radix Astragali and Radix Angelicae Sinensis in Idiopathic Pulmonary Fibrosis

Exploring the role and mechanism of Astragalus membranaceus and radix paeoniae rubra in idiopathic pulmonary fibrosis through network pharmacology and experimental validation

Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix

Unraveling the mechanism of ethyl acetate extract from Prismatomeris connata Y. Z. Ruan root in treating pulmonary fibrosis: insights from bioinformatics, network pharmacology, and experimental validation

Author ' s response to reviews Title : Simultaneous copy number gains of NUPR 1 and ERBB 2 predicting poor prognosis in early-stage breast cancer

DNA methylation modification in Idiopathic pulmonary fibrosis

Complex Involvement of the Extracellular Matrix, Immune Effect, and Lipid Metabolism in the Development of Idiopathic Pulmonary Fibrosis

Mushroom Inonotus sanghuang alleviates experimental pulmonary fibrosis: Implications for therapy of pulmonary fibrosis

Feasibility and Mechanism Analysis of Shenfu Injection in the Treatment of Idiopathic Pulmonary Fibrosis

Genes related to N6-methyladenosine in the diagnosis and prognosis of idiopathic pulmonary fibrosis

Integrative analysis of the efficacy and pharmacological mechanism of Xuefu Zhuyu decoction in idiopathic pulmonary fibrosis via evidence-based medicine, bioinformatics, and experimental verification

Pharmacological mechanism of Astragalus and Angelica in the treatment of idiopathic pulmonary fibrosis based on network pharmacology

Integrating network pharmacology, experimental validation and molecular docking to reveal the alleviation of Yinhuang granule on idiopathic pulmonary fibrosis

Mechanistic Insights into the Treatment of Pulmonary Fibrosis with Bioactive Components from Traditional Chinese Medicine Via Matrix Stiffness-Mediated EMT

Screening study on significant Chinese herb for anti-idiopathic pulmonary fibrosis by combining clinical experience prescriptions and molecular dynamics simulation technologies

Development of early-flowering Kabuli chickpea with compound and simple leaves

Combined Transcriptomic and Proteomic Analysis Reveals the Mechanism of Xing-Qi-Huo-Xue Granules on BLM-induced Pulmonary Fibrosis in Rats

Chinese medicine as a therapeutic option for pulmonary fibrosis: Clinical efficacies and underlying mechanisms